Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its ...

MUTE-Seq is a new liquid-biopsy method powered by an engineered ultra-precise CRISPR enzyme, FnCas9-AF2, which can distinguish single-base mismatches across all sgRNA positions with near-zero ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today shared the results from two oral ...

New NATALEE 5-year sub-analysis data reinforce sustained reduction in distant disease-free survival in broadest population of EBC patients13 ...

When cell division (mitosis) takes too long, it can be a sign that something is wrong with the cells, for example, DNA damage ...

GC Genome, a leading clinical genomics and liquid biopsy company, announced that its study analyzing cell-free DNA (cfDNA) fragmentation patterns in 1,154 healthy individuals has been published in ...

A retrospective real-world analysis presented at the 2025 ASH Annual Meeting and Exposition showed that circulating tumor DNA (ctDNA) detected at the end of treatment (EOT) was a prognostic indicator ...

Measuring the lymphocytes—white blood cells that fight infection—in a patient's blood can be used to predict outcomes in ...

A groundbreaking study introduces new noninvasive screening tools that have the potential to greatly enhance patient comfort ...

The market offers significant opportunities in non-invasive cancer diagnostics using in vitro blood tests, with potential to replace traditional biopsies. Key areas include screening, diagnosis, ...

An Austin, Texas-based genetics-testing company that specializes in cell-free DNA and precision medicine has acquired Foresight Diagnostics Inc., a Boulder-based cancer-diagnostics company.

The treatment success rate for cancer patients improves when doctors detect the disease during its initial stages, because ...